Pharma Deals Review, Vol 2003, No 39 (2003)

Font Size:  Small  Medium  Large

Pozen and Nycomed Enter into Option Agreement for NSAID Lornoxicam

Business Review Editor

Abstract


Pozen entered into an option agreement with Nycomed to acquire rights for Nycomed’s non-steroidal anti-inflammatory drug (NSAID), Lornoxicam for treating pain. The deal could be worth up to US$1.5 M to Nycomed.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.